Department of Bariatric and Metabolic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Expert Rev Anticancer Ther. 2023 Feb;23(2):207-216. doi: 10.1080/14737140.2023.2168647. Epub 2023 Feb 3.
Cyclin-dependent kinase 12 (CDK12) mutation has been shown to be associated with the prognosis and clinicopathological characteristics of various tumors. The aim of this meta-analysis was to investigate the role of mutations in prostate cancer (PCa).
PubMed/Medline, EMBASE, Cochrane Library, and Web of Science database were searched for relevant articles. Meta-analysis was performed by using RevMan5.3 software, and the quality of the included literature was evaluated according to the Newcastle-Ottawa scale (NOS).
A total of 13 studies comprising 5182 participants were enrolled in this meta-analysis. The frequency of CDK12 mutation in PCa was 7.26%. CDK12 mutation was significantly correlated with poor OS/PFS and had a shorter time to progress to CRPC. CDK12 mutant was associated with high-grade Gleason scores, while no relationships were found among CDK12 mutant, age, and the PSA level at diagnosis.
This meta-analysis indicates that patients with CDK12 mutation have poor prognosis in PCa. CDK12 may be used as a biomarker for molecular subtype and a potential therapeutic target of PCa.
细胞周期蛋白依赖性激酶 12（CDK12）突变已被证明与各种肿瘤的预后和临床病理特征有关。本荟萃分析的目的是探讨 CDK12 突变在前列腺癌（PCa）中的作用。
检索了 PubMed/Medline、EMBASE、Cochrane 图书馆和 Web of Science 数据库中的相关文章。使用 RevMan5.3 软件进行荟萃分析，并根据纽卡斯尔-渥太华量表（NOS）评估纳入文献的质量。
本荟萃分析共纳入了 13 项研究，共计 5182 名参与者。PCa 中 CDK12 突变的频率为 7.26%。CDK12 突变与较差的 OS/PFS 显著相关，并且向 CRPC 进展的时间更短。CDK12 突变与高级别 Gleason 评分相关，而与 CDK12 突变、年龄和诊断时 PSA 水平之间无相关性。
本荟萃分析表明，CDK12 突变的患者在 PCa 中预后较差。CDK12 可作为 PCa 分子亚型的生物标志物和潜在的治疗靶点。
